F]DFA accumulation is attenuated in several mouse models of metabolic syndrome, suggesting an association between ribose salvage and glucose and lipid metabolism. These results describe a tool for studying ribose salvage and suggest that plasma ribose is preferentially metabolized in the liver. molecular imaging | sugar metabolism | Slc2a2 R ibose is a naturally occurring monosaccharide whose metabolites contribute to DNA, RNA, and energy production (1) . Most studies and textbooks focus on the intracellular synthesis of ribose-5-phosphate from glucose via the oxidative and nonoxidative pentose phosphate pathways (1) (Fig. 1A) . However, a few studies suggest that cells can also salvage extracellular ribose for further intracellular metabolism (2) . Ribose is likely the second most abundant carbohydrate in blood, being present at ∼100 μM in human fasting serum (3) . Ribose is also present in the diet and is absorbed through the intestines into the blood stream (3) (4) (5) . However, despite the abundance of blood ribose, little is known about ribose salvage, including its biodistribution and regulation.
During salvage, ribose is transported across the cell membrane and phosphorylated by ribokinase (RBKS) to ribose-5-phosphate (6) . Ribose-5-phosphate can be incorporated into nucleic acids via the de novo nucleotide synthesis pathway or metabolized to glycolytic intermediates via the nonoxidative pentose phosphate pathway (1) . Enzymes in the nonoxidative pentose phosphate pathway include transketolase (TKT) and transaldolase 1 (TALDO1), sequential enzymes that transfer carbons between phosphorylated carbohydrate intermediates. An additional enzyme in the nonoxidative pentose phosphate pathway is ribose-5-phosphate isomerase (RPIA), which catalyzes the interconversion of ribose-5-phosphate and ribulose-5-phosphate (1) . Alternatively, the first step to incorporate ribose-5-phosphate into nucleic acids is phosphorylation by phosphoribosyl pyrophosphate synthetase 1 or 2 (PRPS1 or PRPS2) (1) (Fig. 1A) .
Several lines of evidence suggest that blood ribose and ribose salvage could be linked to glucose metabolism. Cells interconvert ribose-5-phosphate and glucose-6-phosphate via the nonoxidative pentose phosphate pathway (1) . Ribose is metabolized to glucose and glucose-6-phosphate in liver slices and liver enzyme extracts (2, 7) . Additionally, fasting serum ribose concentrations (∼100 μM) in humans are similar to plasma and serum concentrations of other gluconeogenic substrates, including pyruvate (∼50 μM) and glycerol (∼100 μM) (8, 9) . Finally, the conversion of ribose to glucose requires less energy and reducing power than either pyruvate or glycerol (1) .
Other data suggest that ribose may have alternative and distinct roles different from those of glucose in the body. Fasting blood ribose concentrations are ∼50-fold lower than blood glucose concentrations (3) . With few exceptions, cells and tissues cannot survive with ribose as their sole carbohydrate source (10) (11) (12) . Additionally, RBKS is substrate-inhibited at ribose concentrations of >0.5 mM, suggesting that cells may limit the amount of ribose they salvage (6) .
PET is used for imaging and quantifying changes in wholebody metabolism through the use of radiolabeled substrates (13 ]FDG has been extensively used both preclinically and clinically to study glucose metabolism in vivo, including to identify metabolic changes during brain development, to monitor myocardial viability, and to image and identify tumors in vivo (13) (14) (15) . We reasoned that a PET probe for measuring and imaging ribose salvage could provide unique and novel information on this understudied pathway in vivo.
Significance
The saccharide ribose is naturally present in food and circulates in the blood. Previous studies suggest that cells internalize ribose directly from the extracellular space, but how, why, and where this occurs in the body are not well understood. Here, we developed a new PET probe to monitor this process in vivo. To understand ribose salvage in vivo better, we developed a PET probe that mimics the structure of ribose. An earlier study showed that human RBKS can metabolize ribose and, with lower affinity, arabinose (6) . This suggested to us that ribose derivatized at the 2-position with a positron-emitting nuclide could be metabolized through the ribose salvage pathway. F]DFA at a 45 ± 1.6% decay-corrected radiochemical yield and 99 ± 0% radiochemical purity, as measured by radio-HPLC and radio-TLC (Fig. 1 B-D (Fig. 1C) . [ 18 F]DFA has a specific activity of 114.8 ± 32.2 Ci/mmol and is stable in mouse plasma for up to 2 h (Fig. 1E) .
It is possible that ribose salvage could mirror glucose consumption and that ribose would accumulate preferentially in the heart and brain. Alternatively, one study using light microscopy radioautography with [ DFA Is Phosphorylated by RBKS and Further Metabolized by TKT. One advantage of FDG as a PET imaging probe is that FDG is trapped in cells as FDG-6-phosphate and is not further metabolized (13) . To understand the properties of DFA as a PET imaging probe better, we studied its metabolism in vitro and in vivo using liquid chromatography/tandem MS (LC/MS/MS) with multiple reaction monitoring (MRM). Human RBKS, TKT, TALDO1, RPIA, PRPS1, and PRPS2, expressed in and isolated from Escherichia coli (SI Materials and Methods), correctly metabolized their natural substrates (Figs. S1 and S2). We then tested these enzymes on DFA and its metabolites. RBKS metabolized DFA to DFA-5-phosphate, and TKT further metabolized DFA-5-phosphate to 4-deoxy-4-fluorosedoheptulose-7-phosphate ( Fig. 3 A and B and full chromatograms in Fig. S3 ). TALDO1, which would normally metabolize the product of the TKT reaction, requires a 4-hydroxyl group on its substrate and did not metabolize 4-deoxy-4-fluorosedoheptulose-7-phosphate (Fig. 3C) . Similarly, RPIA normally metabolizes ribose-5-phosphate but requires a 2-hydroxyl on its substrate and did not metabolize DFA-5-phosphate (Fig. 3D) . Neither PRPS1 nor PRPS2 phosphorylated DFA-5-phosphate to its triphosphate form ( Fig. 3E and full chromatograms in Fig. S3 ). Our in vitro analyses suggest that DFA is metabolized to DFA-5-phosphate and 4-deoxy-4-fluorosedoheptulose-7-phosphate.
Although we identified that RBKS and TKT metabolize DFA in vitro, the levels and activity of each enzyme in vivo could affect the kinetics of DFA metabolism. To investigate the metabolism of DFA in vivo, we injected mice with 12.5 μmol of DFA; extracted tissue metabolites after 30 min, 1 h, and 3 h; and analyzed these metabolites by LC/MS/MS-MRM. Confirming our in vitro metabolite studies and consistent with our [
18 F]DFA biodistribution results, we identified DFA-5-phosphate and 4-deoxy-4-fluorosedoheptulose-7-phosphate but not triphosphorylated DFA in all tissues analyzed ( Fig. 3F and full chromatograms in Fig. S4 ). Both of these metabolites were present at 30 and 60 min but were lower in abundance or not detectable by 3 h postinjection in all of the tissues analyzed (Fig. S5) . This suggests either an unidentified metabolic pathway for these molecules or nonspecific clearance of these metabolites, which occurs 1-3 h postinjection. We failed to identify DFA metabolites in the plasma (Fig. 3G) , suggesting that both DFA-5-phosphate and 4-deoxy-4-fluorosedoheptulose-7-phosphate are trapped in cells. Thus, DFA is metabolized to DFA-5-phosphate and 4-deoxy-4-fluorosedoheptulose-7-phosphate in vivo. Because both of these molecules are charged and not found in plasma, this suggests a potential trapping mechanism for intracellular probe accumulation. Additionally, these data may suggest that the ribose salvage pathway is promiscuous in its substrate specificity, metabolizing ribose as well as a fluorinated derivative of arabinose.
Slc2a2 Can Transport Ribose. A major deficit in our understanding of the ribose salvage pathway is that we do not know which protein or proteins transport ribose into cells. Our [
18 F]DFA PET images, [ 14 C]ribose autoradiography images, and ex vivo biodistribution studies all suggest that ribose strongly accumulates in the liver with additional accumulation in the intestines and kidneys (Fig. 2 A-C, E, and F [ 3 H]ribose accumulation in isolated liver cells (Fig. 4 A and B) . This suggests that the ribose transporter may play an important role in defining the biodistribution of ribose accumulation and that the ribose transporter should be expressed more highly in the liver, kidneys, and intestines relative to other tissues, such as the heart. An earlier study indicates that Cytochalasin B, a promiscuous small-molecule ligand that binds to and blocks glucose transport through the Slc2a family of glucose transporters (19) , blocks ribose salvage in cultured mammalian cells (20) . The best-studied hepatic Slc2a transporter is Slc2a2 (also known as GLUT2) (21) . In agreement with previous reports (22), we found that Slc2a2 mRNA levels are enriched in the liver, kidneys, and intestines (Fig. 4C) . Additionally, Slc2a2 mRNA levels are 27.3 ± 3.7-fold, 10.0 ± 1.5-fold, and 4.1 ± 0.5-fold higher in hepatocytes than in endothelial, Kupffer, or stellate cells, respectively (Fig. 4D) . We hypothesized that Slc2a2 might be a ribose transporter. To determine whether Slc2a2 transports ribose, we overexpressed a mouse Slc2a2-GFP fusion in 293T cells (Fig. 4E) . Overexpressed Slc2a2 localized to the cell surface and increased glucose accumulation from 23.2 ± 3.09 fmol per 5 × 10 4 cells to 66.4 ± 2.82 fmol per 5 × 10 4 cells (Fig. 4 F and G) , indicating correct Slc2a2 function in our system. Slc2a2 overexpression also increased ribose accumulation from 4.10 ± 1.10 fmol per 5 × 10 4 cells to 215.79 ± 21.81 fmol per 5 × 10 4 cells and DFA-5-phosphate levels by 300 ± 60% (Fig. 4 H and I) . The difference in magnitude between ribose and DFA accumulation caused by Slc2a2 overexpression likely represents differences in the affinity of Slc2a2 for ribose and DFA, although the disparity could be the result of additional ribose or DFA transporters. We measured the apparent K 0.5 of mouse Slc2a2 for ribose to be 410 μM (95% confidence interval: 170-960 μM) (Fig. 4J) . Ad libitum-fed mouse serum ribose levels are 14.1 ± 3.2 μM (Fig. 4K) . This suggests that Slc2a2 is a low-affinity ribose transporter at physiological blood ribose levels. Notably, these studies neither prove nor imply that Slc2a2 is a major ribose transporter. Additional studies will be required to quantify the precise contribution of Slc2a2 to cellular ribose accumulation. During Metabolic Syndrome. PET imaging allows for rapid and quantitative analyses of biochemical pathways across different physiological and disease states (13) . We hypothesized that pathological changes in whole-body metabolism could affect ribose salvage. Because ribose and glucose are connected via intracellular metabolism (1) and also share a transporter (Fig. 4 G and H), we focused on models with known alterations in glucose metabolism. We investigated one acute and three chronic mouse models of type I (insulin-dependent) diabetes and metabolic syndrome. The small molecule streptozotocin (STZ) is a pancreatic beta-cell toxin that causes an acute insulin-dependent diabetic phenotype in mice, including hyperglycemia and hypoinsulinemia, within 72 h of treatment (23) . STZ treatment increased mouse blood glucose levels from 270 ± 9 mg/dL to 567 ± 19 mg/dL and decreased insulin levels from 1.89 ± 0.78 ng/mL to 0.16 ± 0.03 ng/mL after 5 d but failed to change hepatic [ Mice with genetic KO of the leptin protein (ob/ob mice), mice with ectopic expression of the Agouti protein (A y /a mice), and mice fed a diet composed of 60% fat (diet-induced obesity mice) are all models of metabolic syndrome characterized by obesity, hyperglycemia, insulin resistance, excess hepatic fat accumulation, and enhanced hepatic lipogenesis (24) (25) (26) (27) (28) . Traditional gluconeogenic substrates, such as lactate and pyruvate, and ATP levels are similar or slightly higher per gram of tissue in the livers of ob/ob mice compared with control mice (29) . Additionally, per gram of tissue, livers of ob/ob mice have enhanced glucose release but no difference in pyruvate uptake (30, 31) . We imaged ribose salvage in all three mouse models at time points when the mice were clearly obese and hyperglycemic (SI Materials and Methods) and found a significant decrease in [ 
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). Serum ribose levels were unaffected in ob/ob mice compared with WT mice (Fig. 5C) 18 F] DFA accumulation in these mice was associated with changes in hepatic ribose-5-phosphate levels, we measured ribose-5-phosphate levels using LC/MS/MS-MRM. Ribose-5-phosphate levels, normalized to tissue weight, were 82.3 ± 3.1% lower in the liver but unchanged in the heart of ob/ob mice and 51.9 ± 8.7% lower in the liver but unchanged in the heart of diet-induced obesity mice (Fig. 5D ). This suggests that dysregulated hepatic ribose salvage and ribose metabolism are associated with metabolic syndrome but not type I diabetes.
Discussion
We have developed a PET probe, [ 18 F]DFA, for studying ribose salvage in vivo, and we use this probe to demonstrate that the activity of the ribose salvage pathway is high in the liver, with additional activity in the kidneys and intestines. We provide evidence that the ribose salvage pathway contributes to hepatic [ 18 F]DFA accumulation, although we cannot exclude the possibility that some of the [
18 F]DFA signal is due to nonspecific accumulation. The protein Slc2a2 transports both ribose and DFA, and Slc2a2 mRNA levels are highly enriched in the liver, kidneys, and intestines. We do not yet know if Slc2a2 is the major ribose transporter in the liver. We identify tissues, such as the muscle and spleen, that salvage ribose but have no detectable Slc2a2 mRNA levels. This suggests the existence of additional ribose transporters.
Ribose salvage occurs in all tissues analyzed, including the heart and brain. Previous studies suggest that exogenous ribose is metabolized to glucose and glucose-6-phosphate in liver protein extracts and liver slices (2, 7) . This suggests that the liver uses ribose as a gluconeogenic substrate. Another study suggests that HeLa cells incorporate as much as 85% of exogenous ribose into nucleic acids (12) . Thus, different cell types and cancer cells may use the ribose salvage pathway to provide precursors for distinct cellular pathways.
We show that metabolic syndrome but not type I diabetes is associated with altered hepatic ribose salvage. Metabolic syndrome is a complex disease that includes disorders like obesity, insulin resistance, glucose intolerance, and hypertension, with the unifying theme that individuals with metabolic syndrome have an increased risk of atherosclerotic cardiovascular disease (32) (33) (34) . Metabolic syndrome is also associated with an increased risk of developing type 2 diabetes (35) . Here, we show that [
18 F] DFA accumulation is diminished in several mouse models of metabolic syndrome. The American Heart Association and National Heart, Lung, and Blood Institute suggest that patients be diagnosed with metabolic syndrome if they possess a majority of the following symptoms: elevated waist circumference, elevated triglycerides, reduced HDL-cholesterol, elevated blood pressure, or elevated fasting glucose levels (35) . [
18 F]DFA imaging would not likely rival the use of these simple criteria as a diagnostic tool. However, metabolic syndrome is associated with interrelated and progressive liver pathologies, including nonalcoholic fatty liver disease (NAFL), nonalcoholic steatohepatitis, liver fibrosis, and hepatocellular carcinoma (34) . Noninvasively diagnosing and staging NAFL remains a clinical challenge (36, 37) . Blood tests for liver function often give a mild phenotype in patients with NAFL, and other liver diseases, such as alcoholic liver disease and autoimmune liver disease, can manifest with similar clinical findings (37) . Imaging modalities, such as ultrasound, are only moderately predictive, and invasive liver biopsies remain the preferred method for diagnosing NAFL (37 Additional studies will be required to identify the mechanisms that explain metabolic syndrome-associated changes in hepatic ribose salvage. Physiologically, changes in hepatic lipid levels or inflammation may contribute to lower ribose salvage. Changes in insulin or insulin signaling would be unlikely to play a role, because ribose salvage is unaffected in our model of insulin-dependent diabetes. One possible molecular mechanism includes changes in RBKS activity. Little is known about the regulation of RBKS activity. However, one study suggests that RBKS activity peaks during the S, G 2 , and M phases of the cell cycle and can be found in both soluble and membrane-associated protein preparations (38) .
It remains to be determined whether changes in ribose salvage contribute to or represent an adaptive response to metabolic syndrome. Our data suggest that the liver is a significant sink for blood ribose. Although we fail to identify changes in serum ribose levels in our model of metabolic syndrome, it remains to be determined whether serum ribose levels are altered in humans with metabolic syndrome. One possibility is that decreased hepatic ribose salvage leads to greater serum ribose levels and enhanced vascular damage. Ribose is greater than 50-fold more efficient than glucose at nonenzymatic glycation of collagen fibers to form advanced glycation end products (AGEs) (39, 40) . AGEs have been suggested to contribute to vascular dysfunction and cardiovascular disease (41) . Even though human blood ribose levels are ∼50-fold lower than blood glucose levels, the dramatically greater propensity of ribose to form AGEs suggests that elevated blood ribose levels could have a significant effect on AGE formation in vivo. Pentosidines are a specific type of Ribose-5-phosphate (R-5-P) levels in the liver and heart of WT and ob/ob mice or mice fed a 10% fat diet (Lean) and mice fed a 60% fat diet (Fat). *P < 0.05; **P < 0.01; ***P < 0.001.
AGE that can form between ribose, lysine, and arginine (42) . Metabolic syndrome is a risk factor for diabetes (35) . Plasma levels of pentosidines are elevated 2.5-fold in diabetics, and serum pentosidine levels in type II diabetes are positively associated with vascular complications (42, 43) . Thus, decreased hepatic ribose salvage could lead to higher blood ribose levels, increased AGE formation, and enhanced vascular damage. Future studies will examine how changes in hepatic ribose salvage affect AGE formation.
Slc2a2 KO mice do not survive past approximately 3 wk of age, but Slc2a2 KO mice with pancreatic overexpression of the glucose transporter Slc2a1 or liver-specific Slc2a2 KO mice are viable (44) (45) (46) . These mice have impaired glycogen mobilization during fasting, liver hyperplasia, and glucose intolerance (45, 46) . Fanconi-Bickel syndrome is an autosomal recessive disorder in humans associated with mutations in Slc2a2 (47) . Hepatic phenotypes of patients with Fanconi-Bickel syndrome include hepatomegaly and enhanced glycogen accumulation (48) . Slc2a2 is a high-capacity glucose transporter (21) , and many phenotypes found in Slc2a2 KO mice and patients with Fanconi-Bickel syndrome are likely caused by altered glucose consumption. However, we show that Slc2a2 also transports ribose. Yeast that lack the homolog of human RBKS show enhanced glycogen accumulation (49) , suggesting that ribose salvage may regulate glycogen levels in yeast. This suggests that some of the phenotypes associated with Slc2a2 knockdown or mutations, such as enhanced glycogen accumulation, may be related to limited ribose salvage. These results will have to be interpreted further as future studies determine the precise contribution of Slc2a2 to ribose salvage.
Studies of in vivo biochemistry and metabolism will require carefully designed and validated chemical probes. Here, we describe and validate a novel PET probe, [ 18 F]DFA. Unlike most other types of chemical probes, PET tracers can be used in vitro, in vivo in mice, and eventually in vivo in humans. [ 18 F]DFA is an analog of ribose with limited metabolism that enables precise measurements of the activity of the ribose salvage pathway. We anticipate that [ 18 F]DFA will provide a powerful tool for advancing our understanding of the ribose salvage pathway in vitro and in vivo.
Materials and Methods
Detailed methods describing [ 18 F]DFA synthesis and characterization, micro-PET/CT imaging, autoradiography, quantitative reverse transcription PCR, transporter studies, LC/MS/MS-MRM, immunoblotting, and plasma ribose level measurements can be found in the SI Materials and Methods. All data represent the mean ± SEM. Statistical analyses were performed using the Student t test in Microsoft Excel. Graphs were created in Microsoft Excel or GraphPad Prism.
